Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Paul Bunn to Angiogenesis Inhibitors

This is a "connection" page, showing publications Paul Bunn has written about Angiogenesis Inhibitors.

 
Connection Strength
 
 
 
0.856
 
  1. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42.
    View in: PubMed
    Score: 0.268
  2. Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86.
    View in: PubMed
    Score: 0.192
  3. Hirsch FR, Franklin WA, Bunn PA. Expression of target molecules in lung cancer: challenge for a new treatment paradigm. Semin Oncol. 2002 Jun; 29(3 Suppl 9):2-8.
    View in: PubMed
    Score: 0.177
  4. Raben D, Helfrich B, Bunn PA. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 2004; 59(2 Suppl):27-38.
    View in: PubMed
    Score: 0.049
  5. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104.
    View in: PubMed
    Score: 0.046
  6. Stewart JM, Chan DC, Simkeviciene V, Bunn PA, Helfrich B, York EJ, Taraseviciene-Stewart L, Bironaite D, Gera L. Bradykinin antagonists as new drugs for prostate cancer. Int Immunopharmacol. 2002 Dec; 2(13-14):1781-6.
    View in: PubMed
    Score: 0.046
  7. Bunn PA, Johnson DH. Seminars in oncology. Introduction. Semin Oncol. 2002 Feb; 29(1 Suppl 4):1-2.
    View in: PubMed
    Score: 0.043
  8. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, P?rol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)